Cardinal Partners


	Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
	January 04, 2008
	Cubist Pharmaceuticals Acquires Illumigen Biosciences
	December 26, 2007
	athenahealth Announces Senior Management Addition and Changes
	December 14, 2007
	Sirtris Pharmaceuticals' SIRT1 Activator Controls Glucose as well as a DPP-4 inhibitor in a Pre-Clinical Model of Type 2 Diabetes
	December 13, 2007
	Sirtris and Harvard Unveil Promising, Novel SIRT1 Activators for Treating Diseases of Aging; Therapeutic Type 2 Diabetes Data Published in the Journal Nature
	November 28, 2007
	Alnylam Announces Grant of Broad Patent Covering RNAi Therapeutics in Germany
	November 26, 2007
	Alnylam Expands Management Team with New Appointments
	November 16, 2007
	Momenta Pharmaceuticals Announces Receipt of FDA Letter -- M-Enoxaparin ANDA Not Approvable in Current Form
	November 06, 2007
	Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2007
	November 01, 2007
	Alnylam Pharmaceuticals Reports Third Quarter 2007 Financial Results
	November 01, 2007
	Campbell Clinic Selects athenahealth's On-Demand Practice Management Service for Greater Financial and Operational Outcomes
	October 29, 2007
	Cubist Pharmaceuticals Reports Third Quarter 2007 Results: Total Revenues $79.8 Million; Net Product Revenues $76.3 Million, +52% vs. Q3 2006
	October 17, 2007
	Alnylam and Collaborators Publish New Pre-clinical Results on RNAi Therapeutics for the Treatment of Huntington's Disease
	October 17, 2007
	Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences
	October 16, 2007
	Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK9 Showing Significant and Durable Reductions in LDL Cholesterol Levels
	October 08, 2007
	Alnylam Grants GeneDesign License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
	October 03, 2007
	Cubist Pharmaceuticals Launches New Product Web Site
	October 03, 2007
	Momenta Pharmaceuticals Announces Executive Promotions
	September 27, 2007
	Alnylam and Collaborators Publish New Paper in the Journal Nature on the In Vivo Efficacy and Safety of RNAi Therapeutics
	September 26, 2007
	CUBICIN Approved for Marketing in Canada
	September 25, 2007
	athenahealth, Inc. Announces Pricing of Initial Public Offering
	September 19, 2007
	Alnylam Announces Closing of Previously Announced Strategic Alliance with Roche
	August 08, 2007
	Alnylam Awarded $38.6 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats
	August 08, 2007
	Healthcare Industry Leader Joins VISICU Board of Directors
	August 06, 2007
	Fluidnet Restarts To Launch Intravenous Pumps
	August 03, 2007
	CUBICIN Approved for S. aureus Bloodstream Infections in South Korea and Taiwan
	August 01, 2007
	Alnylam Receives Allowance from European Patent Office for Tuschl II Patent
	August 01, 2007
	VISICU NAMES NEW VICE PRESIDENT OF SALES
	July 09, 2007
	Roche and Alnylam Form Major Alliance on RNAi Therapeutics
	July 09, 2007
	PSS World Medical Announces 5% Equity Investment in and Exclusive Distribution Agreement with athenahealth
	July 02, 2007
	Athenahealth Files IPO To Sell Up To $86.25M In Stk
	June 25, 2007
	athenahealth, Inc. Files Registration Statement for Proposed Initial Public Offering
	June 22, 2007
	CodeRyte Expands Marketing Team with Industry Experts
	June 19, 2007
	VISICU eICU® PATENT REAFFIRMED …. AGAIN
	June 15, 2007
	MERCY HEALTH NETWORK SELECTS VISICU eICU® PROGRAM
	June 14, 2007
	VISICU Unveils New Features To Improve eICU® Critical Care Patient Management
	May 31, 2007
	AllianceCare Completes Sunrise at Home Merger
	May 31, 2007
	FirstHealth Family Care Centers Select athenahealth’s Web-Based EMR Service for Improved Clinical Workflow
	May 21, 2007
	ATHENAHEALTH ALIGNS WITH THE COLORADO MEDICAL SOCIETY TO OFFER ON-DEMAND PRACTICE MANAGEMENT AND EMR SERVICES TO DOCTORS STATEWIDE
	May 18, 2007
	Oregon Medical Association Aligns with athenahealth to Offer Practice Management Services for Physicians Statewide
	May 14, 2007
	Momenta Pharmaceuticals Initiates Phase I Clinical Study for M118 Subcutaneous Formulation
	May 14, 2007
	Alnylam Establishes New Research Program on Delivery of RNAi Therapeutics at MIT's Center for Cancer Research
	May 09, 2007
	Cubist Reports First Quarter 2007 Results
	April 18, 2007
	Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
	April 17, 2007
	athenahealth Joins With the Iowa Medical Society; Offers On-Demand Clinical and Practice Management Services to Physicians
	April 10, 2007
	Bioconnect Systems Completes $8M Series A Financing
	April 05, 2007
	VISICU WINS TOP INNOVATOR OF THE YEAR AWARD
	April 03, 2007
	Saint Joseph's Opens First eICU(R) Facility in Southeast
	March 30, 2007
	athenahealth to Present at 27th Annual Cowen and Company Healthcare Conference
	March 08, 2007
	Momenta Pharmaceuticals to Present At the Cowen and Company 27th Annual Health Care Conference
	March 08, 2007
	Alnylam to Webcast at the Cowen and Company 27th Annual Health Care Conference
	March 07, 2007
	INEX and Alnylam Announce Allowance of New U.S. Patent Covering Delivery of RNAi Therapeutics
	March 07, 2007
	Sirtris Pharmaceuticals, Inc. Files for Initial Public Offering
	March 01, 2007
	Alnylam and Isis Announce Allowance of First U.S. Patent Covering Human microRNAs
	March 01, 2007
	Cubist Pharmaceuticals to Present at the Leerink Swann & Company Novel Antibiotic Conference
	February 28, 2007
	Alnylam Scientist Awarded Two Industry Honors
	February 28, 2007
	CodeRyte Named a Finalist in the 2007 SIIA Codie Awards
	January 31, 2007
	Alnylam and Inex Form Strategic Technology Alliance to Discover and Develop RNAi Therapeutics with Lipid-Based Delivery Formulations
	January 09, 2007
	Alnylam and Inex Form Strategic Technology Alliance to Discover and Develop RNAi Therapeutics with Lipid-Based Delivery Formulations
	January 09, 2007
	Alnylam Announces Key Product and Business Goals for 2007
	January 08, 2007
	Cubist Pharmaceuticals Announces Fourth Quarter 2006 U.S. Net Product Revenues of $56.2 Million and Full Year 2006 U.S. Net Product Revenues of $189.5 Million
	January 08, 2007
	Alnylam Announces Key Product and Business Goals for 2007
	January 08, 2007
	TWO OF COLORADO'S PREMIER CARDIOLOGY GROUPS SELECT ATHENAHEALTH'S WEB-BASED EMR AND REVENUE CYCLE MANAGEMENT SERVICES
	December 20, 2006
	ATHENAHEALTH AND AGILENCE HEALTH ADVISORS FORGE ALLIANCE; TARGET NEW YORK AND NEW JERSEY PHYSICIAN AND HOSPITAL MARKETS
	December 18, 2006
	Alnylam Announces Closing of Common Stock Offering
	December 15, 2006
	TRIANGLE ORTHOPAEDIC ASSOCIATES SELECTS ATHENAHEALTH'S WEB-BASED PRACTICE MANAGEMENT SERVICE
	December 14, 2006
	Alnylam Announces Proceeds of Common Stock Offering
	December 12, 2006
	Alnylam Announces Public Offering of 4,700,000 Shares of Common Stock
	December 11, 2006
	Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program
	December 05, 2006
	Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in China to AstraZeneca
	December 04, 2006
	Sirtris Pharmaceuticals obtains exclusive rights to key sirtuin technology from MIT
	November 30, 2006
	Alnylam Initiates Clinical Program to Evaluate Anti-Viral Activity for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
	November 28, 2006
	Sirtris Pharmaceuticals: Resveratrol reduces fat and boosts endurance by activation of SIRT1, first aging gene shown to accelerate human metabolism
	November 16, 2006
	NORTHERN NEW ENGLAND METROPOLITAN MEDICAL RESPONSE SYSTEM AND ATHENAHEALTH PILOT NEW EMERGENCY RESPONSE MODEL
	November 15, 2006
	Isis and Alnylam Announce Issued U.S. Patent Broadly Covering Chemical Modifications of Oligonucleotide Therapeutics
	November 11, 2006
	athenahealth Joins with the Arkansas Medical Society; Offers Clinical and Practice Management Services to Physicians
	November 07, 2006
	Thomson acquires NexCura:Patient information and communications added to Healthcare Solutions
	November 07, 2006
	Alnylam and Yale University Scientists Demonstrate Therapeutic Silencing of Disease Target Associated with Acute Lung Injury Using RNAi
	November 06, 2006
	Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2006
	November 03, 2006
	Alnylam Pharmaceuticals Reports Third Quarter 2006 Financial Results
	November 02, 2006
	Research published in Nature by Sirtris scientists is first demonstration in mammals that resveratrol, a sirtuin activator, can treat diseases of aging, such as diabetes. Sirtris Pharmaceuticals doses first diabetes patient in human clinical study.
	November 01, 2006
	Minnesota Hospital Outreach Lab Outsources Accounts Receivable Management to Per-Se Technologies
	October 31, 2006
	ATHENAHEALTH JOINS WITH WASHINGTON STATE MEDICAL ASSOCIATION TO HELP IMPROVE THE FINANCIAL AND CLINICAL PERFORMANCE OF THE STATE'S MEDICAL PRACTICES
	October 27, 2006
	Alnylam to Webcast Conference Call Discussing Third Quarter 2006 Financial Results
	October 26, 2006
	Sirtris Pharmaceuticals to Present at the C.E. Unterberg Towbin Life Sciences Conference, October 30th, 2006
	October 25, 2006
	ATHENAHEALTH FORMS STRATEGIC ALLIANCE WITH LONE STAR MSO TO HELP TEXAS PHYSICIANS BETTER MANAGE THEIR PRACTICES AND IMPROVE COLLECTIONS
	October 24, 2006
	Alnylam Announces Progress in Pre-Clinical Hypercholesterolemia RNAi Therapeutic and microRNA Programs
	October 23, 2006
	Cubist Pharmaceuticals Reports Third Quarter 2006 Results and First Profitable Quarter; GAAP Basic and Diluted Net Income $0.09 Per Share; Net Product Revenues $50.3 Million, up 66% vs. 3Q05
	October 18, 2006
	Alnylam Announces Progress in Pre-clinical Programs at the 36th Annual Society for Neuroscience Meeting
	October 16, 2006
	Alnylam Initiates Phase I Clinical Study of Inhaled Formulation of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
	October 11, 2006
	Alnylam Notified of Defense Appropriation Funding for Ongoing Development of RNAi Therapeutics
	October 04, 2006
	Sirtris Announces Clinical Results from Phase 1 Trials of SRT501, a Sirtuin Therapeutic, Company Initiates Phase 1b Study in Type 2 Diabetes Patients
	October 04, 2006
	Alnylam Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats
	September 28, 2006
	Sirtris Pharmaceuticals CEO to Speak at Technology Review's Emerging Technologies Conference at MIT on September 28th, 2006
	September 26, 2006
	US PATENT OFFICE RE-AFFIRMS VISICU’S eICU® PATENT
	September 26, 2006
	ATHENAHEALTH APPOINTS JAMES MACDONALD AS CHIEF OPERATING OFFICER
	September 25, 2006
	Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML); Collaboration to Focus on RNAi Therapeutics Targeting the JC Virus
	September 20, 2006
	ATHENAHEALTH NAMED AS ONE OF NEW ENGLAND'S FASTEST GROWING COMPANIES FOR THE SECOND STRAIGHT YEAR
	September 18, 2006
	Sirtris Pharmaceuticals Hires Mike Jirousek as SVP of Research
	September 12, 2006
	Sirtris Pharmaceuticals to Present at Think Equity Conference September 13th, 2006
	September 07, 2006
	Alnylam Awarded Federal Grant to Develop RNAi Therapeutics for Pandemic Flu
	September 06, 2006
	MOSES CONE HEALTH SYSTEM CONTINUES TRADITION OF PATIENT CENTRIC CARE WITH eICU® PROGRAM
	July 27, 2006
	VISICU Reports Second Quarter Results
	July 27, 2006
	Alnylam Pharmaceuticals Reports Second Quarter 2006 Financial Results; Increasing Revenue Drives Improvement in Year-over-Year Financials
	July 26, 2006
	Cleveland Clinic Physicians Use Advanced Visualization Technology
	July 25, 2006
	athenahealth introduces Healthcare industry's first economically sustainable, Service-based EMR offering for Medical Practices
	July 25, 2006
	Momenta Pharmaceuticals and Sandoz Sign Exclusive Collaboration to Develop Complex Generics and Follow-On Versions of Biotechnology Drugs
	July 25, 2006
	Sirtris Pharmaceuticals to Present at 5th InternationalMetabolic Diseases Drug Discovery World Summit
	July 20, 2006
	Cubist Pharmaceuticals Reports Second Quarter 2006 Results; Total Revenues $47.8 Million; Net Product Revenues $45.7 Million, up 78% Vs. 2Q05; GAAP Loss $0.09 Per Share; Non-GAAP Income $0.06 Per Share
	July 19, 2006
	Alnylam Receives New Issued U.S. Patent Broadly Covering Small Interfering RNAs and Strengthens Leadership in Intellectual Property for RNAi Therapeutics
	July 18, 2006
	Eclipsys Partners with athenahealthSM to Deliver Unique Ambulatory Care Solution
	July 17, 2006
	Alnylam and INEX Accelerate Collaboration on Systemic Delivery of RNAi Therapeutics; Positive Results for Systemic RNAi Support Advancement to Next Phase of Collaboration
	July 17, 2006
	Alnylam Announces Collaboration with University of Texas Southwestern Medical Center to Discover RNAi Therapeutics for Hypercholesterolemia; Collaboration to Focus on PCSK9, a Key Gene Involved in Metabolism of LDL-Cholesterol
	July 17, 2006
	Remote ICU Saves Lives in Intensive Care
	July 10, 2006
	Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents
	September 04, 00

Current Portfolio News

Archive Portfolio News